![Elena Ridloff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elena Ridloff
Director of Finance/CFO at
SIONNA THERAPEUTICS, INC.
Net worth: 2 M $ as of 2026-05-30
Profile
Ms. Elena H. Ridloff, CFA, is an Independent Director at Kymera Therapeutics, Inc., an Independent Director at Kronos Bio, Inc. and a Chief Financial Officer & Executive Vice President at ACADIA Pharmaceuticals, Inc. She is on the Board of Directors at Kymera Therapeutics, Inc. and Kronos Bio, Inc. Ms. Ridloff was previously employed as a Vice President-Investor Relations by Alexion Pharmaceuticals, Inc., a Chief Executive Officer & Managing Member by BioVision, Inc., a Senior Analyst by Maverick Capital Ltd., and a Senior Analyst by Paramount BioCapital Asset Management, Inc. She received her undergraduate degree from the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-20 | 38,532 ( 0.09% ) | 2 M $ | 2026-05-30 |
Elena Ridloff active positions
| Companies | Position | Start |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Director/Board Member | 2021-03-11 |
| SIONNA THERAPEUTICS, INC. | Director of Finance/CFO | 2020-12-31 |
Former positions of Elena Ridloff
| Companies | Position | End |
|---|---|---|
| KRONOS BIO, INC. | Director/Board Member | 2025-06-19 |
| ACADIA PHARMACEUTICALS INC. | Director of Finance/CFO | 2021-09-09 |
| ALEXION PHARMACEUTICALS, INC. | Investor Relations Contact | 2018-02-28 |
BioVision, Inc.
 BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Chief Executive Officer | 2014-03-31 |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Analyst-Equity | 2011-12-31 |
Training of Elena Ridloff
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
95
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Paramount BioCapital Asset Management manages hedge funds and private equity funds that focus on investments in healthcare and life sciences companies. The firm invests globally, with emphasis on the stocks of small-cap healthcare technology companies. | Finance |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Finance |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Stealth BioTherapeutics, Inc.
 Stealth BioTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat the mitochondrial dysfunctions and age-related diseases | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
- Stock Market
- Insiders
- Elena Ridloff
